Table 3.

Significance, partial eta squared, and observed power for the independent variables in various generalized models (tests of between-subject effects). Therapy and functional limitations were the only significant predictors for the WOMAC Index from baseline to 12 weeks in all models with WOMAC subscales.

Tests of Between-Subject Effects
	Dependent Variable: Changes in WOMAC Index from Baseline to 12 Weeks
	Source	Type III Sum of Squares	df	F	Sig.	Partial Eta Squared	Observed Power
Model I	WOMAC Index baseline	108,356.6	1	104.0	<0.001	0.413	100.0%
	Therapy	37,834.5	1	36.3	<0.001	0.197	100.0%
Model II	WOMAC-A pain baseline	82,636.9	1	68.0	<0.001	0.315	100.0%
	Therapy	37,968.6	1	31.2	<0.001	0.171	100.0%
Model III	WOMAC-B stiffness baseline	67,526.4	1	51.2	<0.001	0.257	100.0%
	Therapy	34,093.8	1	25.9	<0.001	0.149	99.9%
Model IV	WOMAC-C functional limitations baseline	104,845.2	1	98.4	<0.001	0.399	100.0%
	Therapy	37,328.5	1	35.0	<0.001	0.191	100.0%
Model V	WOMAC-A pain baseline	2122.2	1	2.0	0.158	0.014	29.1%
	WOMAC-B stiffness baseline	1630.1	1	1.5	0.216	0.010	23.5%
	WOMAC-C functional limitations baseline	12,576.4	1	11.9	0.001	0.076	92.9%
	Therapy	37,786.1	1	35.8	<0.001	0.197	100.0%
Model VI	WOMAC-A pain baseline	616.4	1	0.6	0.430	0.006	12.3%
	WOMAC-B stiffness baseline	4302.8	1	4.4	0.039	0.041	54.6%
	WOMAC-C functional limitations baseline	11,001.1	1	11.2	0.001	0.097	91.3%
	Age	53.4	1	0.1	0.816	0.001	5.6%
	Duration of pains (years)	35.9	1	0.0	0.849	0.000	5.4%
	BMI	802.1	1	0.8	0.368	0.008	14.6%
	Therapy	14,222.4	1	14.5	<0.001	0.122	96.5%
	Gender	36.1	1	0.0	0.848	0.000	5.4%
	Expectations for Ayurveda	9572.7	4	2.4	0.051	0.086	68.2%
	Expectations for conventional therapy	2068.5	4	0.5	0.716	0.020	17.3%